{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:58:05Z","timestamp":1760954285971},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T00:00:00Z","timestamp":1415836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T00:00:00Z","timestamp":1415836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1038\/gt.2014.100","type":"journal-article","created":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T15:17:33Z","timestamp":1415891853000},"page":"146-154","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC\/Dkk-3 gene therapy for malignant glioma"],"prefix":"10.1038","volume":"22","author":[{"given":"Y","family":"Shimazu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Oka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kumon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Date","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,13]]},"reference":[{"key":"BFgt2014100_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14737140.7.5.641","volume":"7","author":"M Penas-Prado","year":"2007","unstructured":"Penas-Prado M, Gilbert MR . Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 2007; 7: 641\u2013661.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFgt2014100_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987\u2013996.","journal-title":"N Engl J Med"},{"key":"BFgt2014100_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1023\/A:1006444300504","volume":"46","author":"S Chatterjee","year":"2000","unstructured":"Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY . Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol 2000; 46: 135\u2013144.","journal-title":"J Neurooncol"},{"key":"BFgt2014100_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1215\/15228517-2008-016","volume":"10","author":"Y Mizobuchi","year":"2008","unstructured":"Mizobuchi Y, Matsuzaki K, Kuwayama K, Kitazato K, Mure H, Kageji T et al. REIC\/Dkk-3 induces cell death in human malignant glioma. Neuro-Oncology 2008; 10: 244\u2013253.","journal-title":"Neuro-Oncology"},{"key":"BFgt2014100_CR5","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1158\/0008-5472.CAN-05-0829","volume":"65","author":"F Abarzua","year":"2005","unstructured":"Abarzua F, Sakaguchi M, Takaishi M . Adenovirus-mediated overexpression of REIC\/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res 2005; 65: 9617\u20139622.","journal-title":"Cancer Res"},{"key":"BFgt2014100_CR6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/sj.onc.1203503","volume":"19","author":"J Wang","year":"2000","unstructured":"Wang J, Shou J, Chen X . Dickkopf-1: an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 2000; 19: 1843\u20131848.","journal-title":"Oncogene"},{"key":"BFgt2014100_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S0955-0674(96)80115-3","volume":"8","author":"JA Varner","year":"1996","unstructured":"Varner JA, Cheresh DA . Integrins and cancer. Curr Opin Cell Biol 1996; 8: 724\u2013730.","journal-title":"Curr Opin Cell Biol"},{"key":"BFgt2014100_CR8","unstructured":"Varner JA, Cheresh DA . Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Import Adv Oncol 1996; 69\u201387."},{"key":"BFgt2014100_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1091\/mbc.6.6.725","volume":"6","author":"JA Varner","year":"1995","unstructured":"Varner JA, Emerson DA, Juliano RL . Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 1995; 6: 725\u2013740.","journal-title":"Mol Biol Cell"},{"key":"BFgt2014100_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1126\/science.270.5241.1500","volume":"270","author":"M Friedlander","year":"1995","unstructured":"Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA . Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500\u20131502.","journal-title":"Science"},{"key":"BFgt2014100_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.7512751","volume":"264","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Clark RA, Cheresh DA . Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569\u2013571.","journal-title":"Science"},{"key":"BFgt2014100_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","volume":"79","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157\u20131164.","journal-title":"Cell"},{"key":"BFgt2014100_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00441-003-0774-5","volume":"314","author":"KM Hodivala-Dilke","year":"2003","unstructured":"Hodivala-Dilke KM, Reynolds AR, Reynolds LE . Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003; 314: 131\u2013144.","journal-title":"Cell Tissue Res"},{"key":"BFgt2014100_CR14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1083\/jcb.117.5.1101","volume":"117","author":"DI Leavesley","year":"1992","unstructured":"Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA . Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 1992; 117: 1101\u20131107.","journal-title":"J Cell Biol"},{"key":"BFgt2014100_CR15","first-page":"151","volume":"48","author":"TJ MacDonald","year":"2001","unstructured":"MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 151\u2013157.","journal-title":"Neurosurgery"},{"key":"BFgt2014100_CR16","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1158\/1078-0432.CCR-04-1223","volume":"11","author":"A Abdollahi","year":"2005","unstructured":"Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270\u20136279.","journal-title":"Clin Cancer Res"},{"key":"BFgt2014100_CR17","first-page":"4263","volume":"62","author":"PA Burke","year":"2002","unstructured":"Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL . Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002; 62: 4263\u20134272.","journal-title":"Cancer Res"},{"key":"BFgt2014100_CR18","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","volume":"26","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 5610\u20135617.","journal-title":"J Clin Oncol"},{"key":"BFgt2014100_CR19","first-page":"1039","volume":"19","author":"L Tentori","year":"2008","unstructured":"Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 2008; 19: 1039\u20131043.","journal-title":"Oncol Rep"},{"key":"BFgt2014100_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1440-1789.2012.01344.x","volume":"33","author":"M Onishi","year":"2013","unstructured":"Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S et al. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 2013; 33: 162\u2013174.","journal-title":"Neuropathology"},{"key":"BFgt2014100_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/2193-1801-2-160","volume":"2","author":"M Onishi","year":"2013","unstructured":"Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J et al. Gene expression profiling of the anti-glioma effect of Cilengitide. SpringerPlus 2013; 2: 160.","journal-title":"SpringerPlus"},{"key":"BFgt2014100_CR22","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/ijc.24240","volume":"124","author":"T Mikkelsen","year":"2009","unstructured":"Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009; 124: 2719\u20132727.","journal-title":"Int J Cancer"},{"key":"BFgt2014100_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/cgt.2013.38","volume":"20","author":"K Fujii","year":"2013","unstructured":"Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J et al. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 2013; 20: 437\u2013444.","journal-title":"Cancer Gene Ther"},{"key":"BFgt2014100_CR24","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/jnci\/djm229","volume":"99","author":"K Kurozumi","year":"2007","unstructured":"Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007; 99: 1768\u20131781.","journal-title":"J Natl Cancer Inst"},{"key":"BFgt2014100_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2176\/nmc.52.539","volume":"52","author":"K Kurozumi","year":"2012","unstructured":"Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I . Cilengitide treatment for malignant glioma: current status and future direction. Neurol Medico-Chirurg 2012; 52: 539\u2013547.","journal-title":"Neurol Medico-Chirurg"},{"key":"BFgt2014100_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1083\/jcb.152.1.87","volume":"152","author":"S Chen","year":"2001","unstructured":"Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin\/T cell factor-mediated transcription. J Cell Biol 2001; 152: 87\u201396.","journal-title":"J Cell Biol"},{"key":"BFgt2014100_CR27","first-page":"1039","volume":"19","author":"L Tentori","year":"2008","unstructured":"Tentori L, Dorio A, Muzi A, Lacal PM, Ruffini F, Navarra P et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol Rep 2008; 19: 1039\u20131043.","journal-title":"Oncol Rep"},{"key":"BFgt2014100_CR28","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1158\/1078-0432.CCR-04-1223","volume":"11","author":"A Abdollahi","year":"2005","unstructured":"Abdollahi A, Griggs D, Zieher H . Inhibition of \u03b1v\u03b23 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270\u20136279.","journal-title":"Clin Cancer Res"},{"key":"BFgt2014100_CR29","doi-asserted-by":"publisher","first-page":"e4449","DOI":"10.1371\/journal.pone.0004449","volume":"4","author":"GC Alghisi","year":"2009","unstructured":"Alghisi GC, Ponsonnet L, Ruegg C . The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 2009; 4: e4449.","journal-title":"PLoS One"},{"key":"BFgt2014100_CR30","doi-asserted-by":"publisher","first-page":"23467","DOI":"10.1074\/jbc.M110.199539","volume":"286","author":"RJ Burkhalter","year":"2011","unstructured":"Burkhalter RJ, Symowicz J, Hudson LG, Gottardi CJ, Stack MS . Integrin regulation of beta-catenin signaling in ovarian carcinoma. J Biol Chem 2011; 286: 23467\u201323475.","journal-title":"J Biol Chem"},{"key":"BFgt2014100_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2474-4-16","volume":"4","author":"JC Howard","year":"2003","unstructured":"Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B et al. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet Disord 2003; 4: 16.","journal-title":"BMC Musculoskelet Disord"},{"key":"BFgt2014100_CR32","doi-asserted-by":"publisher","first-page":"8333","DOI":"10.1158\/0008-5472.CAN-08-0080","volume":"68","author":"Y Kashiwakura","year":"2008","unstructured":"Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M et al. Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC\/Dickkopf-3-induced apoptosis. Cancer Res 2008; 68: 8333\u20138341.","journal-title":"Cancer Res"},{"key":"BFgt2014100_CR33","first-page":"989","volume":"25","author":"SS Than","year":"2011","unstructured":"Than SS, Kataoka K, Sakaguchi M, Murata H, Abarzua F, Taketa C et al. Intraperitoneal administration of an adenovirus vector carrying REIC\/Dkk-3 suppresses peritoneal dissemination of scirrhous gastric carcinoma. Oncol Rep 2011; 25: 989\u2013995.","journal-title":"Oncol Rep"},{"key":"BFgt2014100_CR34","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.cgt.7701071","volume":"14","author":"K Edamura","year":"2007","unstructured":"Edamura K, Nasu Y, Takaishi M, Kobayashi T, Abarzua F, Sakaguchi M et al. Adenovirus-mediated REIC\/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model. Cancer Gene Ther 2007; 14: 765\u2013772.","journal-title":"Cancer Gene Ther"},{"key":"BFgt2014100_CR35","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","volume":"15","author":"R Stupp","year":"2014","unstructured":"Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100\u20131108.","journal-title":"Lancet Oncol"},{"key":"BFgt2014100_CR36","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1111\/j.1349-7006.2009.01315.x","volume":"100","author":"T Matsuzaki","year":"2009","unstructured":"Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009; 100: 2402\u20132410.","journal-title":"Cancer Sci"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt2014100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt2014100","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt2014100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T12:12:46Z","timestamp":1648555966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt2014100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,13]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["BFgt2014100"],"URL":"https:\/\/doi.org\/10.1038\/gt.2014.100","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,13]]},"assertion":[{"value":"9 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Momotaro-Gene Inc. holds the patents of the Ad-REIC agent and develops the agent as a cancer therapeutic medicine. Dr Kumon, Dr Nasu and Dr Watanabe demonstrated the utility of the agent and also own the stock in Momotaro-Gene Inc. Okayama University and Momotaro-Gene Inc. are working together for the development of the Ad-REIC agent. Okayama University received the GMP-grade Ad-REIC agent from Momotaro-Gene Inc. to perform the clinical trials for the treatment of cancer patients. Okayama University also received research funds for the joint research. Dr Kumon is the Chief Science Officer in Momotaro-Gene Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}